2. Search Result
Search Result
Results for "

NHE3

" in MedChemExpress (MCE) Product Catalog:
Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-100325
    NHE3-IN-1

    		Na+/H+ Exchanger (NHE) Neurological Disease
    NHE3-IN-1 is a sodium/proton exchanger type 3 (NHE-3) inhibitor extracted from patent WO 2011019784 A1.
    NHE3-IN-1
  • HY-139313
    NHE3-IN-2

    		Na+/H+ Exchanger (NHE) Metabolic Disease
    NHE3-IN-2 is a Na +/H + exchanger-3 (NHE3) inhibitor ( patent WO2001079186A1, example 6-Chlor-4-phenyl-2-chinazolinyl-guanidin) .
    NHE3-IN-2
  • HY-101840A
    EIPA hydrochloride
    Maximum Cited Publications
    53 Publications Verification

    L593754 hydrochloride; MH 12-43 hydrochloride; Ethylisopropylamiloride hydrochloride

    		 TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na +/H +-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA hydrochloride
  • HY-101840
    EIPA
    Maximum Cited Publications
    53 Publications Verification

    L593754; MH 12-43; Ethylisopropylamiloride

    		 TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na +/H +-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA
  • HY-15991A
    Tenapanor hydrochloride
    4 Publications Verification

    AZD1722 hydrochloride; RDX5791 hydrochloride

    		 Na+/H+ Exchanger (NHE) Metabolic Disease
    Tenapanor (AZD1722) hydrochloride is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor hydrochloride reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor hydrochloride has the potential for the research of hyperphosphatemia .
    Tenapanor hydrochloride
  • HY-15991
    Tenapanor
    4 Publications Verification

    AZD1722; RDX5791

    		 Na+/H+ Exchanger (NHE) Metabolic Disease
    Tenapanor (AZD1722) is a potent and orally active sodium/hydrogen exchanger isoform 3 (NHE3) inhibitor. Tenapanor reduces intestinal phosphate absorption predominantly through reduction of passive paracellular phosphate flux. Tenapanor has the potential for the research of hyperphosphatemia .
    Tenapanor
  • HY-151360
    NHE3-IN-3

    		Sodium Channel Metabolic Disease
    NHE3-IN-3 (Compound 1) is a Na +/H + exchanger isoform 3 (NHE3) inhibitor with pIC50 of 6.2 and 6.6 against human and rat NHE3, respectively. NHE3-IN-3 shows high (98%) oral bioavailability in Sprague–Dawley rats .
    NHE3-IN-3
  • HY-156696
    S3226

    		Na+/H+ Exchanger (NHE) Cardiovascular Disease
    S3226 is an inhibitor for Na+/H+ exchange subtype 3 (NHE3) with an IC50 of 0.2 µmol/L in rat NHE3 transfected fibroblasts. S3226 exhibits protective activity in rat ischemia-induced acute renal failure models .
    S3226
  • HY-132181
    Dimethylamiloride hydrochloride

    		Na+/H+ Exchanger (NHE) Inflammation/Immunology
    Dimethylamiloride hydrochloride is a Na +/H + exchanger NHE inhibitor with Ki values of 0.02, 0.25, and 14 μM for NHE1, NHE2, and NHE3, respectively. Dimethylamiloride hydrochloride can be used for pain research .
    Dimethylamiloride hydrochloride
  • HY-101840AR
    EIPA hydrochloride (Standard)

    L593754 hydrochloride (Standard); MH 12-43 hydrochloride (Standard); Ethylisopropylamiloride hydrochloride (Standard)

    		 Reference Standards TRP Channel Autophagy COX Prostaglandin Receptor Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (hydrochloride) (Standard) is the analytical standard of EIPA (hydrochloride). This product is intended for research and analytical applications. EIPA (L593754) hydrochloride is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA hydrochloride also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA hydrochloride inhibits macropinocytosis as well. EIPA hydrochloride can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA hydrochloride (Standard)
  • HY-101840R
    EIPA (Standard)

    L593754 (Standard); MH 12-43 (Standard); Ethylisopropylamiloride (Standard)

    		 Reference Standards TRP Channel Prostaglandin Receptor Autophagy COX Na+/H+ Exchanger (NHE) Inflammation/Immunology Cancer
    EIPA (Standard) is the analytical standard of EIPA. This product is intended for research and analytical applications. EIPA (L593754) is an orally active TRPP3 channel inhibitor with an IC50 of 10.5 μM. EIPA also enhances autophagy by inhibiting Na+/H+-exchanger 3 (NHE3). EIPA inhibits macropinocytosis as well. EIPA can be used in the research of inflammation and cancers, such as gastric cancer, colon carcinoma, pancreatic carcinoma [3] .
    EIPA (Standard)
  • HY-18071A
    BI-9627 hydrochloride
    2 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 hydrochloride is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 hydrochloride displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 hydrochloride shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627 hydrochloride
  • HY-18071
    BI-9627
    2 Publications Verification

    		 Na+/H+ Exchanger (NHE) Cardiovascular Disease
    BI-9627 is potent sodium-hydrogen exchanger isoform 1 (NHE1) inhibitor, with IC50s of 6 and 31 nM in intracellular pH recovery (pHi) and human platelet swelling assays, respectively. BI-9627 displays >30-fold selectivity against NHE2 and with no measurable inhibitory activity against the NHE3 isoform. BI-9627 shows low DDI (agent-agent interaction) potential, excellent pharmacokinetics in rat and dog, and remarkably potent activity in the isolated heart model of ischemia-reperfusion injury .
    BI-9627

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: